Featured

Status

Health Topics

Any Category
Diseases
Male Urogenital Diseases
Clear Filters

Search Clinical Trials

29 Results
Completed
Psychosocial and Patient Education Needs of Prostate Cancer Patients Selecting Watchful Waiting
Interviews are conducted over the telephone and require approximately 90 minutes to complete. Men interviewed are compensated for their participation in the study.
Baylor Role: Lead Sponsor
Completed
Screening for Bladder Cancer
Reduction of cancer mortality is a stated goal of the National Cancer Institute. Cancer of the bladder is the 4th most commonly diagnosed cancer and 7th leading cause of cancer …
Baylor Role: Lead Sponsor
Completed
Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment
The major objective of this two-stage phase II study is to determine whether tamoxifen is deserving of further study in metastatic bladder cancer. Tamoxifen is expected to function as a …
Completed
Phase I - Pre-Radical Prostatectomy RTVP-1 Gene Therapy for Prostate Cancer
The population selected for this study includes patients with locally advanced and/or poorly differentiated tumors. These patients have an unacceptably high failure rate when treated by radical prostatectomy alone (over …
Baylor Role: Lead Sponsor
Withdrawn
Symptom Management in African-American Men With Localized Prostate Cancer
OBJECTIVES: - Develop a symptom management intervention for African-American men treated for localized prostate cancer, with a particular emphasis on low health literacy men. OUTLINE: Participants are interviewed by the …
Baylor Role: Lead Sponsor
Completed
Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer
OBJECTIVES: Primary - Evaluate the safety and tolerance of NY-ESO-1/LAGE-1 class-I and class-II vaccine administered subcutaneously in patients with androgen-independent metastatic prostate cancer. Secondary - Compare the response induced by …
Baylor Role: Lead Sponsor
Completed
Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation
OBJECTIVES: - Determine the safety and feasibility of fludarabine, cyclophosphamide, and alemtuzumab in patients with recurrent or metastatic renal cell carcinoma undergoing HLA-matched allogeneic stem cell transplantation. OUTLINE: This is …
Baylor Role: Lead Sponsor
Completed
PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
In murine and human xenograft tumor models, administration of PS-341 weekly was associated with significant antitumor activity. In primate studies using a schedule of twice weekly for six weeks, the …
Baylor Role: Lead Sponsor
Completed
Vector Delivery of the IL-12 Gene in Men With Prostate Cancer
The development of a clinical trial for gene therapy in prostate cancer will be coordinated with our collaborators at Baylor involved in similar studies in order to facilitate the approval …
Baylor Role: Lead Sponsor